Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Laboratories reported healthy Q1 FY26 results with consolidated revenue from operations rising 11.2% year-on-year to Rs. 33,711.4 million (from Rs. 30,318.2 million in Q1 FY25). Consolidated profit after tax grew 21.4% to Rs. 6,679.1 million, with EPS at Rs. 55.56 versus Rs. 45.60. On a standalone basis, revenue grew 11.5% to Rs. 23,721.7 million and total profit (including discontinued operations) rose to Rs. 6,561.6 million from Rs. 5,832.5 million. The quarter included a Rs. 142.9 million exceptional gain from the sale of the Indore manufacturing facility. The company also completed two acquisitions during the quarter — Adroit Biomed (Rs. 1,400 million) and Bombay Ortho Industries (Rs. 1,470 million). The Generic Business is classified as discontinued operations pending transfer to subsidiary Alkem Wellness by October 1, 2025. Auditor Deloitte Haskins & Sells LLP issued an unmodified review report, noting the Q1 FY25 comparatives were previously reviewed by a predecessor auditor.
A solid operational quarter with double-digit revenue and earnings growth, likely to be viewed positively by investors. The exceptional gain, acquisitions, and discontinued operations classification are largely neutral to slightly positive, though the auditor change (Deloitte replacing a predecessor) is a governance point worth noting.